FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283522969> ?p ?o ?g. }

• W4283522969 endingPage "S314" @default.
• W4283522969 startingPage "S314" @default.
• W4283522969 abstract "Sodium-glucose cotransporter 2 inhibitors (SGLT2) and glucagon-like peptide 1 receptor agonists (GLP-1) have been found to potentially decrease adverse cardiovascular outcome risk in clinical trials. The objective of this manuscript is to use a federated, real-world data source to compare the cardiovascular benefits between these two medication classes in patients with Type 2 Diabetes (DM2) and established atherosclerotic cardiovascular disease (ASCVD). Leveraging a global federated data research platform representing over 57 health care organizations, TriNetX Inc, we retrospectively analyzed two cohorts of DM2 patients with established ASCVD initiating either SGLT2 or GLP-1 medications. The primary outcome was a composite outcome of major adverse cardiovascular events (MACE) including cerebral infarction, acute myocardial infarction, acute coronary event, percutaneous coronary intervention, or coronary artery bypass grafting within 3 years following the initiation of an SGLT2 or GLP1 medication. The secondary outcome was all-cause mortality. Propensity score matching was employed to account for observed baseline confounders. The outcomes were estimated using logistic regression. The SGLT2 cohort consisted of 48,059 patients while the GLP-1 cohort consisted of 55,090 patients. 40,266 patients remained after propensity score matching (equal cohorts). The matched cohort had an average age of 66 years, were 68% white, and 57% male. The primary composite outcome showed no significant difference between groups [OR: 0.975, (95% CI: 0.942 thru 1.008)]. The GLP1 cohort was found to have higher odds of all-cause mortality compared to the SGLT-2 cohort [OR: 1.121, (95% CI: 1.053 thru 1.193)]. While no significant difference in cardiovascular events was observed, the finding of reduction of all-cause mortality among patient receiving SGLT2i indicates a potential clinical benefit among patients with both DM2 and ASCVD. Next steps should involve different subpopulations to determine which groups are most likely to benefit from selection of SGLT2 over GLP-1 medication classes." @default.
• W4283522969 created "2022-06-27" @default.
• W4283522969 creator A5047736073 @default.
• W4283522969 creator A5068640213 @default.
• W4283522969 creator A5076785258 @default.
• W4283522969 date "2022-07-01" @default.
• W4283522969 modified "2023-09-27" @default.
• W4283522969 title "CO57 Cardiovascular Outcomes in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Initiating SGLT2 or GLP-1 Medications within Federated-Real-World Data" @default.
• W4283522969 doi "https://doi.org/10.1016/j.jval.2022.04.155" @default.
• W4283522969 hasPublicationYear "2022" @default.
• W4283522969 type Work @default.
• W4283522969 citedByCount "0" @default.
• W4283522969 crossrefType "journal-article" @default.
• W4283522969 hasAuthorship W4283522969A5047736073 @default.
• W4283522969 hasAuthorship W4283522969A5068640213 @default.
• W4283522969 hasAuthorship W4283522969A5076785258 @default.
• W4283522969 hasBestOaLocation W42835229691 @default.
• W4283522969 hasConcept C126322002 @default.
• W4283522969 hasConcept C134018914 @default.
• W4283522969 hasConcept C17923572 @default.
• W4283522969 hasConcept C201903717 @default.
• W4283522969 hasConcept C2777180221 @default.
• W4283522969 hasConcept C2780400711 @default.
• W4283522969 hasConcept C2780739214 @default.
• W4283522969 hasConcept C500558357 @default.
• W4283522969 hasConcept C555293320 @default.
• W4283522969 hasConcept C71924100 @default.
• W4283522969 hasConcept C72563966 @default.
• W4283522969 hasConceptScore W4283522969C126322002 @default.
• W4283522969 hasConceptScore W4283522969C134018914 @default.
• W4283522969 hasConceptScore W4283522969C17923572 @default.
• W4283522969 hasConceptScore W4283522969C201903717 @default.
• W4283522969 hasConceptScore W4283522969C2777180221 @default.
• W4283522969 hasConceptScore W4283522969C2780400711 @default.
• W4283522969 hasConceptScore W4283522969C2780739214 @default.
• W4283522969 hasConceptScore W4283522969C500558357 @default.
• W4283522969 hasConceptScore W4283522969C555293320 @default.
• W4283522969 hasConceptScore W4283522969C71924100 @default.
• W4283522969 hasConceptScore W4283522969C72563966 @default.
• W4283522969 hasIssue "7" @default.
• W4283522969 hasLocation W42835229691 @default.
• W4283522969 hasOpenAccess W4283522969 @default.
• W4283522969 hasPrimaryLocation W42835229691 @default.
• W4283522969 hasRelatedWork W2100465349 @default.
• W4283522969 hasRelatedWork W2372758922 @default.
• W4283522969 hasRelatedWork W2380699085 @default.
• W4283522969 hasRelatedWork W2417949551 @default.
• W4283522969 hasRelatedWork W2918435398 @default.
• W4283522969 hasRelatedWork W3029393331 @default.
• W4283522969 hasRelatedWork W3105417361 @default.
• W4283522969 hasRelatedWork W3136022019 @default.
• W4283522969 hasRelatedWork W4200091933 @default.
• W4283522969 hasRelatedWork W4200403296 @default.
• W4283522969 hasVolume "25" @default.
• W4283522969 isParatext "false" @default.
• W4283522969 isRetracted "false" @default.
• W4283522969 workType "article" @default.